BioCryst Pharmaceuticals (BCRX) Metrics: History & Chart

BioCryst Pharmaceuticals, Inc.(BCRX)

Biotechnology · Durham, NC

$8.15+0.05 (+0.62%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

Durham, NC

435 employees

www.biocryst.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Charles K. Gayer

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-4.37%
30D Total Return	-18.67%
YTD Total Return	+3.85%
1Y Total Return	+13.29%
3Y Total Return	+22.17%
5Y Total Return	-41.01%
10Y Total Return	+76.05%
15Y Total Return	+200.06%
20Y Total Return	-28.16%

2026	+3.85%
2025	+3.72%
2024	+25.54%
2023	-47.82%
2022	-17.11%
2021	+85.91%
2020

CAGR TTM	+13.22%
CAGR 3Y	+6.90%
CAGR 5Y	-10.02%
CAGR 10Y	+5.82%
CAGR 15Y	+7.60%
CAGR 20Y	-1.64%

PE Ratio	7.37
PE Ratio Avg TTM	7.63
PE Ratio Avg 3Y	7.63
Current VS TTM Avg	-3.37%
Current VS 3Y Avg	-3.37%
Current VS 5Y Avg	-3.37%

All Metrics

BCRX Valuation Metrics

BCRX Stock Price Metrics

BCRX Dividend Metrics

BCRX Growth Rate Metrics

BCRX Discounted Cash Flow Metrics

BCRX Returns By Period

BCRX Yearly Returns

BCRX Average Annual Returns By Period (CAGR)

BCRX Revenue Metrics

BCRX PE Ratio Metrics

BCRX PS Ratio Metrics

BCRX PB Ratio Metrics

BCRX Price to Free Cash Flow Ratio Metrics

BCRX Debt to Equity Ratio Metrics

BCRX PEG Ratio Metrics

BCRX FCF Yield

BCRX Earnings Yield

BCRX EBITDA Yield

BCRX OCF Yield

BCRX EV/EBIT Ratio Metrics

BCRX EV/EBITDA Ratio Metrics

BCRX EV/Assets Ratio Metrics

BCRX EV/Sales Ratio Metrics

BCRX Current Ratio Metrics

BCRX Quick Ratio Metrics

BCRX ROIC Metrics

BCRX Return on Assets Metrics

BCRX Return on Equity Metrics

BCRX Net Profit Margin Metrics

BCRX Gross Profit Margin Metrics

BCRX Tax Rate Metrics

PS Ratio	2.28
PS Ratio Avg TTM	2.54
PS Ratio Avg 3Y	3.32
Current VS TTM Avg	-10.35%
Current VS 3Y Avg	-31.26%
Current VS 5Y Avg	-54.02%

PB Ratio	62.87
PB Ratio Avg TTM	68.48
PB Ratio Avg 3Y	12.34
Current VS TTM Avg	-8.19%
Current VS 3Y Avg	+409.42%
Current VS 5Y Avg	+366.71%

PFCF Ratio	6.01
PFCF Ratio Avg TTM	15.65
PFCF Ratio Avg 3Y	15.65
Current VS TTM Avg	-61.61%
Current VS 3Y Avg	-61.61%
Current VS 5Y Avg	-61.61%

Debt/Equity Ratio	(0.90)
Debt/Equity Ratio Avg TTM	(1.91)
Debt/Equity Ratio Avg 3Y	(1.76)
Current VS TTM Avg	+52.83%
Current VS 3Y Avg	+48.83%
Current VS 5Y Avg	+50.85%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	16.63%
FCF Yield Avg TTM	9.91%
FCF Yield Avg 3Y	8.62%
Current VS TTM Avg	+67.79%
Current VS 3Y Avg	+92.97%
Current VS 5Y Avg	+92.97%

Earnings Yield	13.58%
Earnings Yield Avg TTM	13.14%
Earnings Yield Avg 3Y	13.14%
Current VS TTM Avg	+3.34%
Current VS 3Y Avg	+3.34%
Current VS 5Y Avg	+3.34%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	6.70
Ev/Ebit Ratio Avg TTM	28.33
Ev/Ebit Ratio Avg 3Y	28.33
Current VS TTM Avg	-76.35%
Current VS 3Y Avg	-76.35%
Current VS 5Y Avg	-76.35%

Ev/Ebitda Ratio	6.60
Ev/Ebitda Ratio Avg TTM	28.21
Ev/Ebitda Ratio Avg 3Y	28.21
Current VS TTM Avg	-76.60%
Current VS 3Y Avg	-76.60%
Current VS 5Y Avg	-76.60%

Ev/Assets Ratio	4.31
Ev/Assets Ratio Avg TTM	5.07
Ev/Assets Ratio Avg 3Y	4.70
Current VS TTM Avg	-14.99%
Current VS 3Y Avg	-8.38%
Current VS 5Y Avg	-5.18%

Ev/Sales Ratio	2.55
Ev/Sales Ratio Avg TTM	3.26
Ev/Sales Ratio Avg 3Y	4.79
Current VS TTM Avg	-21.75%
Current VS 3Y Avg	-46.73%
Current VS 5Y Avg	-60.53%

Current Ratio	2.32
Current Ratio Avg TTM	2.08
Current Ratio Avg 3Y	2.60
Current VS TTM Avg	+11.42%
Current VS 3Y Avg	-10.77%
Current VS 5Y Avg	-37.24%

Quick Ratio	2.29
Quick Ratio Avg TTM	2.05
Quick Ratio Avg 3Y	2.53
Current VS TTM Avg	+11.57%
Current VS 3Y Avg	-9.46%
Current VS 5Y Avg	-35.47%

ROIC	(89.73%)
ROIC Avg 3Y	(7.99%)
ROIC Avg 5Y	(21.42%)
Current VS 3Y Avg	-1023.17%
Current VS 5Y Avg	-318.94%
Current VS 10Y Avg	-57.13%

ROA	(68.96%)
ROA Avg TTM	(17.87%)
ROA Avg 3Y	(3.05%)
Current VS TTM Avg	-285.94%
Current VS 3Y Avg	-2159.46%
Current VS 5Y Avg	-755.92%

ROE	N/A
ROE Avg TTM	(269.43%)
ROE Avg 3Y	(203.98%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(40.90%)
Net Profit Margin Avg TTM	(70.78%)
Net Profit Margin Avg 3Y	(14.46%)
Current VS TTM Avg	+42.21%
Current VS 3Y Avg	-182.80%
Current VS 5Y Avg	+9.43%

Gross Profit Margin	97.82%
Gross Pft Margin Avg TTM	8.59%
Gross Pft Margin Avg 3Y	98.13%
Current VS TTM Avg	+1038.31%
Current VS 3Y Avg	-0.32%
Current VS 5Y Avg	-0.27%

Tax Rate	1.36%
Tax Rate Avg 3Y	22.65%
Tax Rate Avg 5Y	22.65%
Current VS 3Y Avg	-94.01%
Current VS 5Y Avg	-94.01%
Current VS 10Y Avg	-94.01%